CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab

References

• Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL, Majeti R. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 2011;71(4):1374–84. doi:10.1158/0008-5472.CAN-10-2238. PMID:21177380
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271–85. doi:10.1016/j.cell.2009.05.046. PMID:19632178
   PubMed Web of Science ®Google Scholar
• Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012;109(17):6662–7. doi:10.1073/pnas.1121623109. PMID:22451913
   PubMed Web of Science ®Google Scholar
• Tseng D, Volkmer JP, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, Seita J, Inlay MA, Weiskopf K, Miyanishi M, et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A. 2013;110(27):11103–8. doi:10.1073/pnas.1305569110. PMID:23690610
   PubMed Web of Science ®Google Scholar
• Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, Xu H, Peng H, Fu YX, Xu MM. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 2015;21(10):1209–15. doi:10.1038/nm.3931. PMID:26322579
   PubMed Web of Science ®Google Scholar
• Sockolosky JT, Dougan M, Ingram JR, Ho CC, Kauke MJ, Almo SC, Ploegh HL, Garcia KC. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc Natl Acad Sci U S A. 2016;113(19):E2646–54. doi:10.1073/pnas.1604268113. PMID:27091975
   PubMed Web of Science ®Google Scholar
• Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, Jr, van Rooijen N, Weissman IL. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286–99. doi:10.1016/j.cell.2009.05.045. PMID:19632179
   PubMed Web of Science ®Google Scholar
• Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-hodgkin lymphoma. Cell. 2010;142(5):699–713. doi:10.1016/j.cell.2010.07.044. PMID:20813259
   PubMed Web of Science ®Google Scholar
• Subramanian S, Parthasarathy R, Sen S, Boder ET, Discher DE. Species- and cell type-specific interactions between CD47 and human SIRPalpha. Blood. 2006;107(6):2548–56. doi:10.1182/blood-2005-04-1463. PMID:16291597
   PubMed Web of Science ®Google Scholar
• Piccione EC, Juarez S, Liu J, Tseng S, Ryan CE, Narayanan C, Wang L, Weiskopf K, Majeti R. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. MAbs. 2015;7(5):946–56. doi:10.1080/19420862.2015.1062192. PMID:26083076
   PubMed Web of Science ®Google Scholar
• Dheilly E, Moine V, Broyer L, Salgado-Pires S, Johnson Z, Papaioannou A, Cons L, Calloud S, Majocchi S, Nelson R, et al. Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies. Mol Ther. 2017;25(2):523–33. doi:10.1016/j.ymthe.2016.11.006. PMID:28153099
   PubMed Web of Science ®Google Scholar
• Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, Tso JY. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy. J Immunol. 1994;152(5):2385–92. PMID:8133049
   PubMed Web of Science ®Google Scholar
• Mazor Y, Hansen A, Yang C, Chowdhury PS, Wang J, Stephens G, Wu H, Dall'Acqua WF. Insights into the molecular basis of a bispecific antibody's target selectivity. MAbs 2015;7(3):461–9. doi:10.1080/19420862.2015.1022695. PMID:25730144
   PubMed Web of Science ®Google Scholar
• Mazor Y, Sachsenmeier KF, Yang C, Hansen A, Filderman J, Mulgrew K, Wu H, Dall'Acqua WF. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. Sci Rep. 2017;7:40098. doi:10.1038/srep40098. PMID:28067257
   PubMed Web of Science ®Google Scholar
• Chen J, Zhong M, Guo H, Davidson D, Mishel S, Lu Y, Rhee I, Pérez-Quintero L, Zhang S, Cruz-Munoz M, et al. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via mac-1 integrin. Nature. 2017;544(7651):493–7. doi:10.1038/nature22076. PMID:28424516
   PubMed Web of Science ®Google Scholar
• Sachdeva M, Dhingra S. Obinutuzumab: A FDA approved monoclonal antibody in the treatment of untreated chronic lymphocytic leukemia. Int J Applied Basic Medical Res. 2014;5(1):54–7.
   Google Scholar
• Herter S, Umana P, Bacac M. Obinutuzumab (GA101) more potently engages phagocytic-lineage cells resulting in enhanced monocyte and macrophage activity when compared to rituximab and ofatumumab. Blood Am Society Hematol. 2013;122(21):5136
   Google Scholar
• Kikuchi Y, Uno S, Yoshimura Y, Otabe K, Iida S, Oheda M, Fukushima N, Tsuchiya M. A bivalent single-chain fv fragment against CD47 induces apoptosis for leukemic cells. Biochem Biophys Res Commun. 2004;315(4):912–8. doi:10.1016/j.bbrc.2004.01.128. PMID:14985099
   PubMed Web of Science ®Google Scholar
• Wiersma VR, He Y, Samplonius DF, van Ginkel RJ, Gerssen J, Eggleton P, Zhou J, Bremer E, Helfrich W. A CD47-blocking TRAIL fusion protein with dual pro-phagocytic and pro-apoptotic anticancer activity. Br J Haematol. 2014;164(2):304–7. doi:10.1111/bjh.12617. PMID:24164421
   PubMed Web of Science ®Google Scholar